Watch PolyPid Ltd for free: we tell you when fair value or trend changes.

PolyPid Ltd (PYPD) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of PolyPid Ltd stock $3.33, price $6.31, that is 47.2% below the price, quality 27 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

EstimateBear $2.50 to bull $4.16 Growth analysisrevenue history, year by year Quality 27/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Israel · ISIN IL0011326795

Thin data Nov 11, 2026

PolyPid Ltd

PYPD · US

Very expensive, weak quality

Our calculation puts a fair price 47% below what the stock costs today.

Low debt

Fair value $3.33 · Strongly overvalued

Quality 27/100

Negative free cash flow

Trails peers (3/8)

Narrow moat 0/100

Thin data

Estimate

Watch PolyPid Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $2.40 – $284.40 · fair‑value band $2.50 – $4.16 · the $6.31 price screens above the $3.33 fair value. As of Nov 11, 2026.

Follow PolyPid in your weekly email

Every Wednesday you see whether PolyPid is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.

Show moreShow less

Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors.

PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Stock analysis

PolyPid Ltd (PYPD) currently trades at $6.31, while our estimate is $3.33, 47% below the price, so the stock looks overvalued today.

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.50 (bear) to $4.16 (bull), the price of $6.31 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

PolyPid Ltd reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$34.2M in FY2025.

Key figures

Market cap $143M Micro · EPS (TTM) $−1.44 · Return on equity −244% · Return on assets (EBIT) −131% (5-year average) · Free cash flow −$28.1M · Net cash $3.6M.

What moves the price

The share trades at its 52-week high and 76% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −47%, PYPD screens richer than that median.

Fair Value

Bear $2.50 Fair Value $3.33 Bull $4.16

Price $6.31 · Downside -47.2%

Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0

How much profit the company makes from its sales and capital

Quality Growth 25

Are margins and returns getting better?

Cashflow 21

Do the profits arrive as real cash?

Financial strength 65

Debt, balance sheet and risk of trouble

Investment 50

Does it invest with discipline instead of growing at any price?

Low Volatility 16

How calm the share price moves, does not count

Price momentum 86

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 100

Distance to the 52-week high, does not count

New shares 0

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

PYPD screens overvalued: fair value 47% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare PolyPid Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/7 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 27 · Bottom 25%

Fair Value upside −47.2% · Bottom 25%

Profitability

Return on assets −153.2% · Bottom 25%

Operating margin (12 months) 0.0% · Above median

Growth and dividend

Revenue growth (quarter YoY) 0.0% · Above median

Balance sheet

Debt / equity 0.06× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 13.02× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)0 · sector 0

PAST (return on equity)0 · sector 0

HEALTH (low debt)97 · sector 96

DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Regeneron Pharmaceuticals, Inc REGN	$916.06	$1,275	+39%	vs PYPD
Samsung Biologics Co 207940	1,468,000 KRW	1,661,000 KRW	+13%	vs PYPD
Vertex Pharmaceuticals Incorporated VRTX	$547.89	$601.80	+10%	vs PYPD
Genmab A/S GMAB	kr 3,581	kr 3,880	+8%	vs PYPD
argenx SE ARGX	$971.55	$908.40	−7%	vs PYPD
CSL Limited CSL	A$201.68	A$181.40	−10%	vs PYPD
Moderna, Inc MRNA	$250.83	$158.70	−37%	vs PYPD
BeOne Medicines AG 6160	HK$252.20	HK$152.80	−39%	vs PYPD
Celltrion, Inc 068270	203,000 KRW	74,945 KRW	−63%	vs PYPD
Royalty Pharma plc RPRX	$69.45	$19.01	−73%	vs PYPD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks Stocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PolyPid Ltd: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/PYPD?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/PYPD.US.svg" width="360" height="84" alt="PolyPid Ltd: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "PolyPid Ltd Fair Value". https://www.fairvalue-calculator.com/stock/PYPD

Frequently asked questions

Is PolyPid Ltd (PYPD) overvalued or undervalued?

As of Nov 11, 2026, our estimate of fair value is $3.33 versus a price of $6.31, about 47% lower (overvalued).

What is the fair value of PYPD?

Our estimate for PolyPid Ltd is $3.33 (as of Nov 11, 2026), built from audited fundamentals. The current price: $6.31.

What is the quality score of PYPD?

PolyPid Ltd has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for PolyPid Ltd (PYPD)?

Our calculated price target is the estimate of $3.33 (as of Nov 11, 2026). Cautious scenario $2.50, optimistic scenario $4.16. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.

What is the PolyPid Ltd stock forecast for 2026?

Our estimate puts fair value at $3.33, about 47% lower versus a price of $6.31 (overvalued). Cautious scenario $2.50, optimistic scenario $4.16. The calculation is refreshed regularly with new filings.

What is the intrinsic value of PolyPid Ltd (PYPD)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PolyPid Ltd it is $3.33 per share (as of Nov 11, 2026), against a price of $6.31.

Is PolyPid Ltd stock overvalued or undervalued in 2026?

As of Nov 11, 2026, PYPD trades above its calculated fair value: price $6.31, fair value $3.33, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of PYPD?

No. The price is what the market pays today ($6.31); the fair value is what the company's own numbers justify ($3.33). For PolyPid Ltd the two are $2.98 per share apart. That gap is exactly why we show both numbers side by side.

How much is PolyPid Ltd worth?

The market values PolyPid Ltd at about $143M (market capitalisation, as of Nov 11, 2026). Per share that is $6.31; our models calculate a fair value of $3.33 per share.

What do the bullish and bearish scenarios say about PYPD?

Our models span a range for PolyPid Ltd: cautious scenario $2.50, base $3.33, optimistic $4.16 per share (as of Nov 11, 2026, price $6.31). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of PolyPid Ltd (PYPD)?

Balance-sheet figures for PolyPid Ltd (as of Nov 11, 2026): return on equity −243.6%, debt of 0.06 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.

How far is PYPD from its 52-week high?

PolyPid Ltd trades at $6.31, at its 52-week high of $6.31 and 76% above the low of $3.58 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $3.33 is for.

Which stocks are comparable to PolyPid Ltd?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is PolyPid Ltd stock attractive at the current price?

The data as of Nov 11, 2026: price $6.31, calculated fair value $3.33 (−47%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

Is it still worth investing in stocks now?

The global stock market currently sits 15.1% above its aggregate fair value. PolyPid Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of PolyPid Ltd (PYPD)?

The closing price on Nov 10, 2026 was $6.31. Our estimate is $3.33, about 47% lower (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with PolyPid Ltd right now?

The price sits above even our optimistic bull case ($4.16). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of PolyPid Ltd

How large is the market capitalisation of PolyPid Ltd (PYPD)?

The market capitalisation of PolyPid Ltd is $143M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of PolyPid Ltd (PYPD)?

Earnings per share at PolyPid Ltd are $−1.44. Earnings per share over the last twelve months: total profit spread across every single share.

What is the return on equity of PolyPid Ltd (PYPD)?

The return on equity (ROE) of PolyPid Ltd is −244% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of PolyPid Ltd (PYPD)?

On an EBIT basis the return on assets of PolyPid Ltd is −131% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

How much free cash flow does PolyPid Ltd (PYPD) generate?

The free cash flow of PolyPid Ltd is −$28.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does PolyPid Ltd (PYPD) hold?

PolyPid Ltd holds more cash than debt, $3.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch PolyPid Ltd in the live analysis

One click puts PolyPid Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.